Page last updated: 2024-10-30

metformin and Amentia

metformin has been researched along with Amentia in 26 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"To synthesize the best available evidence on the association of metformin-use with risk, progression, and severity of dementia."8.98Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis. ( Aromataris, E; Bellman, SM; Campbell, JM; Chapman, I; de Courten, B; Stephenson, MD, 2018)
"Despite the launching of numerous new oral antiglycemic agents, metformin may provide further benefit on lowering risk of dementia beyond conventional glycemic control according to the real-world evidence."8.31Metformin Adherence Reduces the Risk of Dementia in Patients With Diabetes: A Population-based Cohort Study. ( Chan, L; Chen, PC; Chen, WT; Chien, LN; Hong, CT, 2023)
"Metformin users compared with sulfonylurea users were associated with a lower risk of all-cause dementia, AD and VD but not with PD or MCI."8.12Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. ( Duijn, CMV; Fernandes, M; Ghose, U; Launer, LJ; Li, QS; Linden, AB; Molero, Y; Nevado-Holgado, AJ; Newby, D; Sproviero, W; Winchester, L, 2022)
"Metformin, a diabetes drug with anti-aging cellular responses, has complex actions that may alter dementia onset."8.12Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia. ( Albers, MW; Betensky, RA; Blacker, D; Boswell, S; Charpignon, ML; Das, S; Evans, K; Finkelstein, SN; Hyman, BT; Magdamo, C; Middleton, L; Rodriguez, S; Sheu, YH; Sokolov, A; Somai, M; Su, B; Tzoulaki, I; Vakulenko-Lagun, B; Welsch, RE; Zheng, B, 2022)
"Results do not support initiating metformin earlier to prevent cognitive decline and, thus, may dampen enthusiasm for metformin as a potential antidementia drug."7.96Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy. ( Barthold, D; Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF; Zubatsky, M, 2020)
"The aim of this study is to investigate the association between metformin usage and dementia in an elderly Korean population."7.96Metformin use in elderly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort. ( Bae, YJ; Choi, EA; Han, YE; Kang, HT; Kim, HS; Kim, J; Kim, Y; Kim, YS; Lee, HC; Lee, JW; You, HS, 2020)
" Metformin use has been associated with a lower risk of dementia compared with sulfonylureas."7.91Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients. ( Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF, 2019)
" Differences between users and non-users of insulin, metformin and sulfonylurea were assessed in each cohort for cognitive and brain MRI measures using linear regression models, and cognitive decline and dementia/AD risk using mixed effect models and Cox regression analyses, respectively."7.91Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts. ( Beeri, MS; Beiser, AS; Conner, S; Davis-Plourde, KL; Ding, J; Haan, MN; Himali, JJ; Ikram, MA; Launer, LJ; Lee, A; Moshier, E; Rawlings, AM; Sedaghat, S; Selvin, E; Seshadri, S; van Duijn, CM; Weinstein, G, 2019)
"To compare incident dementia risk among patients who initiated treatment with metformin or sulfonylurea in Veterans Health Affairs (VHA) patients with replication in Kaiser Permanente Washington (KPW) patients to determine whether first-choice antidiabetic medications are associated with reduced risk of dementia."7.91Metformin and Sulfonylurea Use and Risk of Incident Dementia. ( Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF, 2019)
"The effect of pioglitazone was compared with that of other second-line glucose-lowering drugs on the risk of dementia among individuals with type 2 diabetes receiving metformin-based dual therapy."7.88Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. ( Hsieh, CY; Li, CY; Lu, CH; Ou, HT; Yang, CY, 2018)
" In the present study, we investigated the potential therapeutic effects of metformin (Met) and saxagliptin (Saxa), as insulin sensitizing agents, in a rat model of brain aging and AD using D-galactose (D-gal, 150 mg/kg/day, s."7.85Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. ( Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H, 2017)
"This was a retrospective cohort study of US veterans ≥65 years of age with type 2 diabetes who were new users of metformin or a sulfonylurea and had no dementia."7.85Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. ( Cho, K; Cormack, J; Driver, JA; Gagnon, DR; Orkaby, AR, 2017)
"Long-term use of pioglitazone was associated with a lower dementia incidence."7.81Effect of pioglitazone medication on the incidence of dementia. ( Doblhammer, G; Fink, A; Heneka, MT, 2015)
"Metformin is a safe and effective medication for Type 2 diabetes (T2D) that has been proposed to decrease the risk of aging related disorders including Alzheimer's Disease (AD) and AD related disorders (ADRD)."7.01Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias. ( Luchsinger, JA; Tahmi, M, 2023)
"Dementia was ascertained by ICD9-CM or A-code."6.76Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. ( Hsu, CC; Lee, MS; Tsai, HN; Wahlqvist, ML, 2011)
"This analysis indicated that patients with type 2 diabetes under treatment with DPP-4 inhibitors presented with the lowest risk of dementia, followed by those treated with metformin and thiazolidinedione, while treatment with insulin was associated with the highest risk."5.05Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis. ( Han, M; Simó, R; Tang, X; Yang, J; Zhou, JB, 2020)
"To synthesize the best available evidence on the association of metformin-use with risk, progression, and severity of dementia."4.98Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis. ( Aromataris, E; Bellman, SM; Campbell, JM; Chapman, I; de Courten, B; Stephenson, MD, 2018)
"Despite the launching of numerous new oral antiglycemic agents, metformin may provide further benefit on lowering risk of dementia beyond conventional glycemic control according to the real-world evidence."4.31Metformin Adherence Reduces the Risk of Dementia in Patients With Diabetes: A Population-based Cohort Study. ( Chan, L; Chen, PC; Chen, WT; Chien, LN; Hong, CT, 2023)
"Metformin, a diabetes drug with anti-aging cellular responses, has complex actions that may alter dementia onset."4.12Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia. ( Albers, MW; Betensky, RA; Blacker, D; Boswell, S; Charpignon, ML; Das, S; Evans, K; Finkelstein, SN; Hyman, BT; Magdamo, C; Middleton, L; Rodriguez, S; Sheu, YH; Sokolov, A; Somai, M; Su, B; Tzoulaki, I; Vakulenko-Lagun, B; Welsch, RE; Zheng, B, 2022)
"Metformin users compared with sulfonylurea users were associated with a lower risk of all-cause dementia, AD and VD but not with PD or MCI."4.12Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. ( Duijn, CMV; Fernandes, M; Ghose, U; Launer, LJ; Li, QS; Linden, AB; Molero, Y; Nevado-Holgado, AJ; Newby, D; Sproviero, W; Winchester, L, 2022)
"Dual therapy with metformin (Met) + dipeptidyl peptidase-4 inhibitor (DPP-4i), Met + thiazolidinedione (TZD), and sulfonylurea (SU) + thiazolidinediones (TZD) were significantly associated with all-cause dementia (HR = 0."4.02The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study. ( Han, K; Kim, WJ; Noh, JH; Park, CY, 2021)
"The aim of this study is to investigate the association between metformin usage and dementia in an elderly Korean population."3.96Metformin use in elderly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort. ( Bae, YJ; Choi, EA; Han, YE; Kang, HT; Kim, HS; Kim, J; Kim, Y; Kim, YS; Lee, HC; Lee, JW; You, HS, 2020)
"Results do not support initiating metformin earlier to prevent cognitive decline and, thus, may dampen enthusiasm for metformin as a potential antidementia drug."3.96Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy. ( Barthold, D; Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF; Zubatsky, M, 2020)
" Differences between users and non-users of insulin, metformin and sulfonylurea were assessed in each cohort for cognitive and brain MRI measures using linear regression models, and cognitive decline and dementia/AD risk using mixed effect models and Cox regression analyses, respectively."3.91Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts. ( Beeri, MS; Beiser, AS; Conner, S; Davis-Plourde, KL; Ding, J; Haan, MN; Himali, JJ; Ikram, MA; Launer, LJ; Lee, A; Moshier, E; Rawlings, AM; Sedaghat, S; Selvin, E; Seshadri, S; van Duijn, CM; Weinstein, G, 2019)
" Metformin use has been associated with a lower risk of dementia compared with sulfonylureas."3.91Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients. ( Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF, 2019)
"To compare incident dementia risk among patients who initiated treatment with metformin or sulfonylurea in Veterans Health Affairs (VHA) patients with replication in Kaiser Permanente Washington (KPW) patients to determine whether first-choice antidiabetic medications are associated with reduced risk of dementia."3.91Metformin and Sulfonylurea Use and Risk of Incident Dementia. ( Dublin, S; Farr, SA; Floyd, JS; Morley, JE; Salas, J; Scherrer, JF, 2019)
"001, 95% CI) with age, dementia, changes in blood red cell counts, memory, and with the taking of metformin and proton pump inhibitors (P=."3.88[Vitamin B ( Camarero-Shelly, M, 2018)
"The effect of pioglitazone was compared with that of other second-line glucose-lowering drugs on the risk of dementia among individuals with type 2 diabetes receiving metformin-based dual therapy."3.88Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. ( Hsieh, CY; Li, CY; Lu, CH; Ou, HT; Yang, CY, 2018)
" In the present study, we investigated the potential therapeutic effects of metformin (Met) and saxagliptin (Saxa), as insulin sensitizing agents, in a rat model of brain aging and AD using D-galactose (D-gal, 150 mg/kg/day, s."3.85Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. ( Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H, 2017)
"To identify distinct temporal likelihoods of age-related comorbidity (ARC) diagnoses: cardiovascular diseases (CVD), cancer, depression, dementia, and frailty-related diseases (FRD) in older men with type 2 diabetes (T2D) but ARC naïve initially, and assess the heterogeneous effects of metformin on ARCs and mortality."3.85Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. ( Espinoza, SE; Habib, SL; Jo, B; Lorenzo, C; Wang, CP, 2017)
"This was a retrospective cohort study of US veterans ≥65 years of age with type 2 diabetes who were new users of metformin or a sulfonylurea and had no dementia."3.85Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. ( Cho, K; Cormack, J; Driver, JA; Gagnon, DR; Orkaby, AR, 2017)
"Long-term use of pioglitazone was associated with a lower dementia incidence."3.81Effect of pioglitazone medication on the incidence of dementia. ( Doblhammer, G; Fink, A; Heneka, MT, 2015)
"Metformin is a safe and effective medication for Type 2 diabetes (T2D) that has been proposed to decrease the risk of aging related disorders including Alzheimer's Disease (AD) and AD related disorders (ADRD)."3.01Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias. ( Luchsinger, JA; Tahmi, M, 2023)
"Dementia was ascertained by ICD9-CM or A-code."2.76Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. ( Hsu, CC; Lee, MS; Tsai, HN; Wahlqvist, ML, 2011)
"Insulin resistance is considered to play an important role in the associations between DM and dementia."2.53Impact of Insulin Sensitizers on the Incidence of Dementia: A Meta-Analysis. ( Luo, YJ; Xiao, J; Ye, F; Yi, G; Yu, NW, 2016)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (46.15)24.3611
2020's14 (53.85)2.80

Authors

AuthorsStudies
Tabatabaei Malazy, O1
Bandarian, F1
Qorbani, M1
Mohseni, S1
Mirsadeghi, S1
Peimani, M1
Larijani, B1
Wu, CY1
Shapiro, L1
Ouk, M1
MacIntosh, BJ1
Black, SE1
Shah, BR1
Swardfager, W1
Newby, D1
Linden, AB1
Fernandes, M1
Molero, Y1
Winchester, L1
Sproviero, W1
Ghose, U1
Li, QS1
Launer, LJ2
Duijn, CMV1
Nevado-Holgado, AJ1
Charpignon, ML2
Vakulenko-Lagun, B2
Zheng, B2
Magdamo, C2
Su, B2
Evans, K2
Rodriguez, S2
Sokolov, A2
Boswell, S2
Sheu, YH2
Somai, M2
Middleton, L2
Hyman, BT2
Betensky, RA2
Finkelstein, SN2
Welsch, RE2
Tzoulaki, I2
Blacker, D2
Das, S2
Albers, MW2
Chen, PC1
Hong, CT1
Chen, WT1
Chan, L1
Chien, LN1
Tahmi, M1
Luchsinger, JA1
Fyfe, I1
Salas, J3
Morley, JE3
Scherrer, JF3
Floyd, JS3
Farr, SA3
Zubatsky, M1
Barthold, D1
Dublin, S3
Zhou, JB1
Tang, X1
Han, M1
Yang, J1
Simó, R1
Secnik, J1
Xu, H1
Schwertner, E1
Hammar, N1
Alvarsson, M1
Winblad, B1
Eriksdotter, M1
Garcia-Ptacek, S1
Religa, D1
Kim, Y1
Kim, HS1
Lee, JW1
Kim, YS1
You, HS1
Bae, YJ1
Lee, HC1
Han, YE1
Choi, EA1
Kim, J1
Kang, HT1
Violante-Cumpa, JR1
Pérez-Arredondo, LA1
González-González, JG1
Mancillas-Adame, LG1
Samaras, K1
Crawford, JD1
Draper, B1
Trollor, JN1
Brodaty, H1
Sachdev, PS1
Kim, WJ1
Noh, JH1
Han, K1
Park, CY1
Camarero-Shelly, M1
Kenawy, S1
Hegazy, R1
Hassan, A1
El-Shenawy, S1
Gomaa, N1
Zaki, H1
Attia, A1
Orkaby, AR1
Cho, K1
Cormack, J1
Gagnon, DR1
Driver, JA1
Lu, CH1
Yang, CY1
Li, CY1
Hsieh, CY1
Ou, HT1
Campbell, JM1
Stephenson, MD1
de Courten, B1
Chapman, I1
Bellman, SM1
Aromataris, E1
Weinstein, G1
Davis-Plourde, KL1
Conner, S1
Himali, JJ1
Beiser, AS1
Lee, A1
Rawlings, AM1
Sedaghat, S1
Ding, J1
Moshier, E1
van Duijn, CM1
Beeri, MS1
Selvin, E1
Ikram, MA1
Haan, MN1
Seshadri, S1
Heneka, MT1
Fink, A1
Doblhammer, G1
Ye, F1
Luo, YJ1
Xiao, J1
Yu, NW1
Yi, G1
Wang, CP1
Lorenzo, C1
Habib, SL1
Jo, B1
Espinoza, SE1
Hsu, CC1
Wahlqvist, ML1
Lee, MS1
Tsai, HN1

Reviews

6 reviews available for metformin and Amentia

ArticleYear
The effect of metformin on cognitive function: A systematic review and meta-analysis.
    Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:6

    Topics: Alzheimer Disease; Cognition; Cognitive Dysfunction; Dementia; Disease Progression; Humans; Metformi

2022
Glucose-lowering drugs, cognition, and dementia: The clinical evidence.
    Neuroscience and biobehavioral reviews, 2022, Volume: 137

    Topics: Cognition; Dementia; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Humans;

2022
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias.
    The journal of prevention of Alzheimer's disease, 2023, Volume: 10, Issue:4

    Topics: Alzheimer Disease; Animals; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin

2023
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
    Metabolism: clinical and experimental, 2020, Volume: 109

    Topics: Bayes Theorem; Dementia; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypo

2020
Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis.
    Journal of Alzheimer's disease : JAD, 2018, Volume: 65, Issue:4

    Topics: Cognitive Dysfunction; Dementia; Diabetes Mellitus; Disease Progression; Humans; Hypoglycemic Agents

2018
Impact of Insulin Sensitizers on the Incidence of Dementia: A Meta-Analysis.
    Dementia and geriatric cognitive disorders, 2016, Volume: 41, Issue:5-6

    Topics: Aged; Dementia; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Risk Factors; Thiazolidi

2016

Trials

1 trial available for metformin and Amentia

ArticleYear
Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
    Journal of Alzheimer's disease : JAD, 2011, Volume: 24, Issue:3

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Cohort Studies; Dementia; Diabetes Mellitus, Type 2;

2011

Other Studies

19 other studies available for metformin and Amentia

ArticleYear
Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus.
    BMJ open diabetes research & care, 2022, Volume: 10, Issue:5

    Topics: Aged; Dementia; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Mid

2022
Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia.
    Nature communications, 2022, Dec-10, Volume: 13, Issue:1

    Topics: Dementia; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Medical Record

2022
Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia.
    Nature communications, 2022, Dec-10, Volume: 13, Issue:1

    Topics: Dementia; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Medical Record

2022
Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia.
    Nature communications, 2022, Dec-10, Volume: 13, Issue:1

    Topics: Dementia; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Medical Record

2022
Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia.
    Nature communications, 2022, Dec-10, Volume: 13, Issue:1

    Topics: Dementia; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Medical Record

2022
Metformin Adherence Reduces the Risk of Dementia in Patients With Diabetes: A Population-based Cohort Study.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2023, Volume: 29, Issue:4

    Topics: Cohort Studies; Dementia; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulins;

2023
Metformin protects against dementia in diabetes.
    Nature reviews. Neurology, 2023, Volume: 19, Issue:12

    Topics: Dementia; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin

2023
Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy.
    Pharmacoepidemiology and drug safety, 2020, Volume: 29, Issue:6

    Topics: Aged; Biomarkers; Dementia; Diabetes Mellitus; Drug Administration Schedule; Female; Glycated Hemogl

2020
Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
    Journal of Alzheimer's disease : JAD, 2020, Volume: 76, Issue:4

    Topics: Aged; Aged, 80 and over; Cohort Studies; Dementia; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase I

2020
Metformin use in elderly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort.
    Diabetes research and clinical practice, 2020, Volume: 170

    Topics: Cohort Studies; Dementia; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence;

2020
Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691-2701.
    Diabetes care, 2021, Volume: 44, Issue:4

    Topics: Aged; Aging; Cognitive Dysfunction; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin

2021
Response to Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691-2701.
    Diabetes care, 2021, Volume: 44, Issue:4

    Topics: Aged; Aging; Cognitive Dysfunction; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin

2021
The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study.
    Journal of Alzheimer's disease : JAD, 2021, Volume: 81, Issue:3

    Topics: Aged; Databases, Factual; Dementia; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; D

2021
[Vitamin B
    Semergen, 2018, Volume: 44, Issue:3

    Topics: Adult; Age Factors; Aged; Dementia; Female; Humans; Longitudinal Studies; Male; Mass Screening; Metf

2018
Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Adamantane; Aging; Animals; Biomarkers; Body Weight; Brain; Dementia; Dipeptides; Galactose; Glycate

2017
Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
    Neurology, 2017, Oct-31, Volume: 89, Issue:18

    Topics: Age Factors; Aged; Aged, 80 and over; Cohort Studies; Dementia; Diabetes Mellitus, Type 2; Female; H

2017
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
    Diabetologia, 2018, Volume: 61, Issue:3

    Topics: Aged; Dementia; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; L

2018
Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts.
    PloS one, 2019, Volume: 14, Issue:2

    Topics: Alzheimer Disease; Brain; Cognition; Cohort Studies; Dementia; Humans; Hypoglycemic Agents; Incidenc

2019
Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients.
    Annals of family medicine, 2019, Volume: 17, Issue:4

    Topics: Age Factors; Aged; Black or African American; Comorbidity; Dementia; Diabetes Mellitus, Type 2; Fema

2019
Metformin and Sulfonylurea Use and Risk of Incident Dementia.
    Mayo Clinic proceedings, 2019, Volume: 94, Issue:8

    Topics: Age Factors; Aged; Databases, Factual; Dementia; Diabetes Mellitus, Type 2; Dose-Response Relationsh

2019
Effect of pioglitazone medication on the incidence of dementia.
    Annals of neurology, 2015, Volume: 78, Issue:2

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Dementia; Diabetes Mellitus; Female;

2015
Differential effects of metformin on age related comorbidities in older men with type 2 diabetes.
    Journal of diabetes and its complications, 2017, Volume: 31, Issue:4

    Topics: Aged; Aged, 80 and over; Aging; Cardiovascular Diseases; Cohort Studies; Comorbidity; Dementia; Depr

2017